Royal Sense Ltd
Founded in 2023, Royal Sense Limited deals in Medical Equipment, Surgical Instruments, Surgical Consumables, Laboratory Equipment, Laboratory Reagents, Medical Disposables and Diagnostic Kits.[1]
- Market Cap ₹ 93.1 Cr.
- Current Price ₹ 190
- High / Low ₹ 198 / 104
- Stock P/E 54.4
- Book Value ₹ 37.4
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.08 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| 4.64 | 8.03 | 18.96 | |
| 3.95 | 7.09 | 16.62 | |
| Operating Profit | 0.69 | 0.94 | 2.34 |
| OPM % | 14.87% | 11.71% | 12.34% |
| 0.00 | 0.01 | 0.04 | |
| Interest | 0.00 | 0.00 | 0.06 |
| Depreciation | 0.00 | 0.00 | 0.01 |
| Profit before tax | 0.69 | 0.95 | 2.31 |
| Tax % | 26.09% | 26.32% | 25.97% |
| 0.51 | 0.70 | 1.71 | |
| EPS in Rs | 1.48 | 2.03 | 3.49 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 3.45 | 3.45 | 4.90 |
| Reserves | 0.51 | 0.70 | 13.44 |
| 0.27 | 0.28 | 1.60 | |
| 2.08 | 1.27 | 0.94 | |
| Total Liabilities | 6.31 | 5.70 | 20.88 |
| 0.04 | 0.04 | 0.05 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.04 | 0.04 | 0.43 |
| 6.23 | 5.62 | 20.40 | |
| Total Assets | 6.31 | 5.70 | 20.88 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| -2.24 | 0.40 | -0.81 | |
| -0.08 | 0.00 | -3.73 | |
| 3.45 | 0.01 | 13.13 | |
| Net Cash Flow | 1.12 | 0.40 | 8.59 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 317.80 | 58.18 | |
| Inventory Days | 68.13 | 71.68 | |
| Days Payable | 177.15 | 47.42 | |
| Cash Conversion Cycle | 208.79 | 82.44 | |
| Working Capital Days | 236.78 | 178.64 | |
| ROCE % |
Documents
Announcements
-
Closure of Trading Window
18h - Closure of trading window for financial results approval.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 23Rd September, 2024
23 Sep - Increase in authorized share capital and preferential allotment.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1)(D) SEBI (LODR) Regulations,2015
18 Sep - Board meeting to discuss fund raising and acquisitions.
-
Intimation Pursuant To Regulation 30 Of SEBI(LODR)Regulations, 2015
13 Sep - Royal Sense Limited launches new pharmaceutical products.
- Revised Outcome For The Financial Results For The Quarter And Year Ended 31St March, 2024 12 Sep
Annual reports
No data available.
Business Profile[1] Royal Sense Ltd. (RSL) supplies materials to hospitals, laboratories, institutions and clinics for health services.